103 related articles for article (PubMed ID: 18824608)
1. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.
Huang F; Drda K; MacGregor TR; Scherer J; Rowland L; Nguyen T; Ballow C; Castles M; Robinson P
Antimicrob Agents Chemother; 2009 Jan; 53(1):95-103. PubMed ID: 18955519
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P
J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991
[TBL] [Abstract][Full Text] [Related]
4. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
[TBL] [Abstract][Full Text] [Related]
5. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
[TBL] [Abstract][Full Text] [Related]
6. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
7. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Ford SL; Reddy YS; Anderson MT; Murray SC; Fernandez P; Stein DS; Johnson MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2201-6. PubMed ID: 16723584
[TBL] [Abstract][Full Text] [Related]
8. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
Reddy YS; Ford SL; Anderson MT; Murray SC; Ng-Cashin J; Johnson MA
Antimicrob Agents Chemother; 2007 Apr; 51(4):1202-8. PubMed ID: 17261626
[TBL] [Abstract][Full Text] [Related]
10. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
11. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.
Martin DE; Blum R; Wilton J; Doto J; Galbraith H; Burgess GL; Smith PC; Ballow C
Antimicrob Agents Chemother; 2007 Sep; 51(9):3063-6. PubMed ID: 17576843
[TBL] [Abstract][Full Text] [Related]
16. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
Sekar VJ; De Pauw M; Mariën K; Peeters M; Lefebvre E; Hoetelmans RM
Antivir Ther; 2007; 12(4):509-14. PubMed ID: 17668559
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
[TBL] [Abstract][Full Text] [Related]
19. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
Chittick GE; Zong J; Blum MR; Sorbel JJ; Begley JA; Adda N; Kearney BP
Antimicrob Agents Chemother; 2006 Apr; 50(4):1304-10. PubMed ID: 16569845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
